Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as UBX1325 injection 50 μL
UBX1325 50 μL · 1 trial · 1 indication
Ocular and systemic safety and tolerability of a repeat IVT injection of UBX1325 compared to active-control (aflibercept) evaluated by treatment emergent adverse events (TEAEs) through Week 24
| Arm | Type | Description |
|---|---|---|
| UBX1325 | EXPERIMENTAL | - |
| Aflibercept (EYLEA ®) | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| UBX1325 injection 50 μL | DRUG | Patients randomized to the UBX1325 arm will receive UBX1325 on Day 1, Weeks 4, 24, and 28 |
| EYLEA® (aflibercept) Injection 2 mg (0.05mL) | DRUG | Patients randomized to the active-control aflibercept arm will receive aflibercept per label every 8 weeks starting from day 1 until Week 40. In addition, these patients will receive UBX1325 on Week 24 and Week 32; and a sham procedure at Week 4 and Week 28. |
Inclusion Criteria: * Patients aged ≥50 years. * Active CNV associated with age-related macular degeneration as evidenced on FA and SD-OCT with presence of intraretinal or subretinal fluid at Screening and Day 1 * BCVA in the study eye (most affected) of 70 to 20 ETDRS letters (equivalent to 20/40 ...
UBX1325 50 μL is an investigational small molecule being studied for the treatment of neovascular age-related macular degeneration, an eye condition in which abnormal blood vessels grow under the retina. It is administered as an injection and is being developed by Unity Biotechnology, Inc. (ticker UBX).
UBX1325 50 μL is being developed by Unity Biotechnology, Inc., which trades on the Nasdaq under the ticker UBX. Unity Biotechnology is the sponsor of the clinical program evaluating this small molecule injection in patients with neovascular age-related macular degeneration.
UBX1325 50 μL is in Phase 2 clinical development. It is an investigational therapy and has not been approved by the FDA. The Phase 2 program includes one completed trial, and no trials of this asset are currently listed as active.
UBX1325 50 μL has been evaluated in the Phase 2 ENVISION study, registered as NCT05275205. The trial enrolled 51 patients with neovascular age-related macular degeneration across sites in the United States, was randomized, double-blind, and active-controlled, and is now completed.
Yes. UBX1325 50 μL and UBX1325 injection 50 μL refer to the same investigational product from Unity Biotechnology, Inc. The 50 μL designation describes the injected volume of the small molecule formulation studied in patients with neovascular age-related macular degeneration.